Featured Research

from universities, journals, and other organizations

Using a molecular switch to turn on cancer vaccines

Date:
March 7, 2011
Source:
Journal of Clinical Investigation
Summary:
Researchers have attempted to capitalize upon natural immune responses against tumors to develop new therapies by generating dendritic cells (DCs) to use as vaccines to augment the T-cell responses of cancer patients. In a new study, researchers improved DC maturation protocols for vaccine production. They engineered a form of the adaptor protein MyD88 that induced downstream signaling in response to a drug. The researchers hope that this "switch" might be broadly applicable to the design of DC vaccines.

The immune system is capable of recognizing tumor growth, and naturally mounts an anti-cancer defense. Dendritic cells (DCs) can take up tumor-derived molecules (antigens) and present them to T cells, and those "primed" T cells are then able to recognize and kill tumor cells.

In recent years, researchers have attempted to capitalize upon these natural immune responses to develop new therapies- namely, by generating a pool of tumor antigen-pulsed DCs that might be used as vaccines to augment the T-cell responses of cancer patients. In clinical trials, these DC vaccines have had limited success, in part because the protocols to generate mature and active DCs in vitro are imperfect. Specifically, generation of mature DCs requires activation of Toll-Like receptors (TLRs), usually achieved by administration of lipopolysaccharide, which can cause toxic shock in humans and can promote apoptosis.

In a new paper, David Spencer and colleagues, of Baylor University in Houston, Texas, addressed this problem by looking to the adaptor molecule downstream of the TLR, MyD88. They engineered a form of MyD88 that could induce downstream signaling in response to a drug, and expressed this inducible MyD88 (iMyD88) in DCs.

Further, the researchers combined iMyD88 with a second pathway required for optimal activation of DCs- CD40 signaling- so that they could control both pathways with administration of a single drug. This combination improved DC-mediated tumor antigen-specific T cell responses in mouse cancer models and T cell responses to human tumor antigens. The researchers hope that this "switch" might be broadly applicable to the design of DC vaccines.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Priyadharshini Narayanan, Natalia Lapteva, Mamatha Seethammagari, Jonathan M. Levitt, Kevin M. Slawin, David M. Spencer. A composite MyD88/CD40 'switch' synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI44327

Cite This Page:

Journal of Clinical Investigation. "Using a molecular switch to turn on cancer vaccines." ScienceDaily. ScienceDaily, 7 March 2011. <www.sciencedaily.com/releases/2011/03/110307124520.htm>.
Journal of Clinical Investigation. (2011, March 7). Using a molecular switch to turn on cancer vaccines. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2011/03/110307124520.htm
Journal of Clinical Investigation. "Using a molecular switch to turn on cancer vaccines." ScienceDaily. www.sciencedaily.com/releases/2011/03/110307124520.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins